drugset / Trial / NCT02146391

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

NCT02146391

Phase 1 Completed 12 enrolled Repros Therapeutics Inc.
CrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, single-center, single-dose, two-way crossover study of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each receive a single dose of Androxal 25 mg in both the fed and fasting state.

Timeline

Start
2014-06
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 25 mg

Indications

No indication recorded.